D. E. Shaw & Co., Inc. Cv Rx, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Cv Rx, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 45,269 shares of CVRX stock, worth $523,762. This represents 0.0% of its overall portfolio holdings.

Number of Shares

45,269

Previous 59,059 23.35%

Holding current value

$523,762

Previous $520,000 10.19%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$6.95 - $15.83 $95,840 - $218,295	-13,790 Reduced 23.35%	45,269 $573,000
Q3 2024 Nov 14, 2024	SELL	$7.15 - $12.37 $35,957 - $62,208	-5,029 Reduced 7.85%	59,059 $520,000
Q2 2024 Aug 14, 2024	BUY	$6.49 - $19.2 $290,550 - $859,564	44,769 Added 231.74%	64,088 $768,000
Q1 2024 May 15, 2024	SELL	$17.99 - $30.49 $376,962 - $638,887	-20,954 Reduced 52.03%	19,319 $351,000
Q4 2023 Feb 14, 2024	BUY	$11.67 - $33.01 $243,226 - $687,994	20,842 Added 107.26%	40,273 $1.27 Million
Q3 2023 Nov 14, 2023	SELL	$13.56 - $18.47 $895,353 - $1.22 Million	-66,029 Reduced 77.26%	19,431 $294,000
Q2 2023 Aug 14, 2023	BUY	$8.57 - $15.44 $524,981 - $945,823	61,258 Added 253.11%	85,460 $1.32 Million
Q1 2023 May 15, 2023	BUY	$7.08 - $19.4 $83,338 - $228,357	11,771 Added 94.69%	24,202 $225,000
Q4 2022 Feb 14, 2023	BUY	$8.94 - $18.35 $111,133 - $228,108	12,431 New	12,431 $228,000
Q2 2022 Aug 15, 2022	SELL	$4.7 - $7.22 $280,016 - $430,153	-59,578 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.62 - $12.37 $334,828 - $736,979	59,578 New	59,578 $357,000

Others Institutions Holding CVRX

# of Institutions

Shares Held

15.4M

Call Options Held

76.5K

Put Options Held

6.3K

View Full List

About CVRx, Inc.

Ticker CVRX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 20,576,200
Market Cap $238M
Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...

More about CVRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account